Cantor Fitzgerald Forecasts Septerna FY2025 Earnings

Septerna, Inc. (NASDAQ:SEPN) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Septerna in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings of ($2.58) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $50.00 price objective on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share.

A number of other brokerages have also recently commented on SEPN. JPMorgan Chase & Co. assumed coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price target for the company. Wells Fargo & Company assumed coverage on shares of Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price target on the stock. Finally, TD Cowen began coverage on Septerna in a report on Tuesday, November 19th. They issued a “buy” rating on the stock.

Septerna Price Performance

NASDAQ:SEPN opened at $18.38 on Thursday. The business’s fifty day moving average is $22.41. Septerna has a 12 month low of $15.86 and a 12 month high of $28.99.

Insiders Place Their Bets

In other Septerna news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the firm’s stock in a transaction on Monday, October 28th. The shares were acquired at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the purchase, the insider now directly owns 6,215,591 shares of the company’s stock, valued at $111,880,638. This trade represents a 6.34 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.

Hedge Funds Weigh In On Septerna

An institutional investor recently bought a new position in Septerna stock. SG Americas Securities LLC acquired a new stake in Septerna, Inc. (NASDAQ:SEPN) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,095 shares of the company’s stock, valued at approximately $185,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.